Washington D.C., District of Columbia
Phase 3 cancer trials in Washington D.C., DC
58 Phase 3 cancer studies are recruiting participants at sites in Washington D.C. as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Washington D.C. at a glance
- 58 studies are recruiting at a site in Washington D.C..
- By phase: Phase 2/3 (6), Phase 3 (52).
- By sponsor: industry (33), university, hospital or other (18), government (7).
- By research area: Lung Cancer (17), Breast Cancer (16), Lymphoma (9), Prostate Cancer (8), Melanoma (4), Pancreatic Cancer (4).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Washington D.C.
Basic details from each study's public record (the 30 most recently updated of 58). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Washington Hospital Center ( Site 0098)
- Registry record
- NCT06841354 · updated
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Georgetown Uni Hospital
- Registry record
- NCT05894239 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Sibley Memorial Hospital
- Registry record
- NCT06058377 · updated
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Genentech, Inc.
- Study site
- MedStar Washington Hospital Center
- Registry record
- NCT07541079 · updated
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Relay Therapeutics, Inc.
- Study site
- Georgetown University Medical Center
- Registry record
- NCT06982521 · updated
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Gilead Sciences
- Study sites
- MedStar Georgetown University Hospital · MedStar Washington Hospital Center
- Registry record
- NCT05633654 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study sites
- George Washington University Medical Center · Kaiser Permanente-Capitol Hill Medical Center · MedStar Georgetown University Hospital
- Registry record
- NCT05879926 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Kaiser Permanente-Capitol Hill Medical Center · MedStar Georgetown University Hospital · MedStar Washington Hospital Center
- Registry record
- NCT06748222 · updated
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- MedStar Washington Hospital Center
- Registry record
- NCT07174336 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.
Lung cancer studies recruiting in Washington D.C.
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Washington Hospital Center ( Site 0037)
- Registry record
- NCT06422143 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Kaiser Permanente-Capitol Hill Medical Center · MedStar Georgetown University Hospital · MedStar Washington Hospital Center
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- George Washington University Medical Center
- Registry record
- NCT06096844 · updated
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- OSE Immunotherapeutics
- Study site
- Georgetown Lombardi Comprehensive Cancer Center
- Registry record
- NCT06472245 · updated
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- Washington DC Veterans Affairs Medical Center
- Registry record
- NCT06758401 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- George Washington University Medical Center
- Registry record
- NCT04181060 · updated
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Sibley Memorial Hospital
- Registry record
- NCT06119581 · updated
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Sibley Memorial Hospital
- Registry record
- NCT06890598 · updated
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study sites
- MEDSTAR Washington Hospital Center (MedStar Health Research Institute) · MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH)
- Registry record
- NCT06712316 · updated
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Takeda
- Study site
- MedStar Georgetown Cancer Institute-Oncology Research
- Registry record
- NCT07217301 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.
Prostate cancer studies recruiting in Washington D.C.
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Sibley Memorial Hospital
- Registry record
- NCT04423211 · updated
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- MedStar Georgetown University Hospital · MedStar Washington Hospital Center
- Registry record
- NCT06931340 · updated
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
- Registry record
- NCT07164443 · updated
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Washington DC Veterans Affairs Medical Center ( Site 0056)
- Registry record
- NCT06925737 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.
Lymphoma studies recruiting in Washington D.C.
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Sibley Memorial Hospital
- Registry record
- NCT06337318 · updated
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study site
- Sibley Memorial Hospital
- Registry record
- NCT06724237 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Sibley Memorial Hospital
- Registry record
- NCT04269902 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's National Medical Center · MedStar Georgetown University Hospital
- Registry record
- NCT05675410 · updated
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Georgetown University
- Registry record
- NCT06084936 · updated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- MedStar Georgetown University Hospital
- Registry record
- NCT07188558 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Washington D.C., DC on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Washington D.C.
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study site
- Investigative Site US013
- Registry record
- NCT07522073 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.
Ask about studies near Washington D.C.
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections